Citation: Beeson JG, Rogerson SJ, Mueller I, Richards JS, Fowkes FJI (2011) Intermittent Preventive Treatment to Reduce the Burden of Malaria in Children: New Evidence on Integration and Delivery. PLoS Med 8(2): e1000410. doi:10.1371/journal.pmed.1000410
Published: February 1, 2011
Copyright: © 2011 Beeson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors received no specific funding for this article.
Competing interests: Stephen J. Rogerson is on the Editorial Board of PLoS Medicine.
Abbreviations: AQ, amodiaquine; AS, artesunate; IPT, intermittent preventive treatment; IPTc, intermittent preventive treatment during childhood; IPTi, intermittent preventive treatment in infants; IPTp, intermittent preventive treatment in pregnancy; ITN, insecticide-treated bed net; RCH, reproductive and child health; SP, sulfadoxine-pyrimethamine; VHW, village health worker; WHO, World Health Organization
Provenance: Commissioned; not externally peer reviewed.
Linked Research Articles
This Perspective discusses the following new studies published in PLoS Medicine:
1. Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, et al. (2011) Intermittent Preventive Treatment of Malaria Provides Substantial Protection against Malaria in Children Already Protected by an Insecticide-Treated Bednet in Mali: A Randomised, Double-Blind, Placebo-Controlled Trial. PLoS Med 8(2): e1000407. doi:10.1371/journal.pmed.1000407.
A randomized trial reported by Alassane Dicko and colleagues shows that intermittent preventive treatment for malaria in children who are protected from mosquitoes using insecticide-treated bednets provides substantial protection from malaria.
2. Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, et al. (2011) Intermittent Preventive Treatment of Malaria Provides Substantial Protection against Malaria in Children Already Protected by an Insecticide-Treated Bednet in Burkina Faso: A Randomised, Double-Blind, Placebo-Controlled Trial. PLoS Med 8(2): e1000408. doi:10.1371/journal.pmed.1000408.
A randomized trial reported by Diadier Diallo and colleagues shows that intermittent preventive treatment for malaria in children who are protected from mosquitoes using insecticide-treated bednets provides substantial protection from malaria.
3. Bojang KA, Akor F, Conteh L, Webb E, Bittaye O, et al. (2011) Two Strategies for the Delivery of IPTc in an Area of Seasonal Malaria Transmission in The Gambia: A Randomised Controlled Trial. PLoS Med 8(2): e1000409. doi:10.1371/journal.pmed.1000409.
Kalifa Bojang and colleagues report a randomized trial showing that delivery of intermittent preventive treatment for malaria in children by village health workers is more effective than delivery by reproductive and child health trekking clinics.
Over the past decade, there has been a substantial increase globally in the coverage of effective interventions to reduce morbidity and mortality from malaria. Insecticide-treated bed nets (ITNs), indoor residual spraying with insecticides, and the use of more effective antimalarials have been the cornerstones of such measures, and there are now clear signs of a sustained reduction in the burden of malaria in many regions. However, further interventions are urgently needed to capitalise on recent progress and sustain the malaria control and elimination effort.
Intermittent Preventive Treatment of Malaria
One approach to help reduce the burden of malaria caused by Plasmodium falciparum is intermittent preventive treatment (IPT), which involves periodic therapeutic doses of antimalarials to reduce the incidence of malaria and prevalence of anemia ,. Previous efforts to use sustained chemoprophylaxis to prevent malaria were complicated by drug toxicity and safety concerns, promoting drug resistance, rebound increases in malaria once chemoprophylaxis ended, and logistical challenges in implementing such an intervention at the population level . Instead, IPT seeks to balance these factors by providing treatments that are frequent enough to have significant benefit, without the downsides of chemoprophylaxis. It appears to act in part by post-treatment prophylactic effects , while drug levels remain above inhibitory concentrations; long-acting drugs such as sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) have been widely used. IPT in pregnancy (IPTp) reduces anemia and low birth weight , and is now recommended by the World Health Organization (WHO) for all pregnant women at risk in sub-Saharan Africa. IPT in infants (IPTi) decreases malaria episodes by 22%–59% . Since malaria is a major cause of illness and death of children under 5 years , recent studies have evaluated the potential for using IPT during childhood (known as IPTc) –, including three new papers in PLoS Medicine that add to the growing evidence base –.
New Evidence for IPTc in the Context of Established Interventions
IPTc appears to be highly effective at reducing clinical malaria episodes in children under 5 with protective efficacy against symptomatic malaria of 69% or higher –. Two new trials add to our understanding by studying the efficacy of IPTc in the context of established interventions. These trials in Burkina Faso and Mali, published in PLoS Medicine, now show that the protective efficacy of IPTc extends to children sleeping under ITNs ,. Both trials showed a high level of protective efficacy against symptomatic malaria (70% in Burkina Faso and 82% in Mali), together with reductions in moderately severe anaemia (56% and 48%, respectively) and severe malaria (69% and 87%, respectively). All children were given an ITN and were randomised to receive three doses, at monthly intervals, of SP plus AQ, or placebo, during the transmission season. Previous IPTc trials, in areas with seasonal peaks of transmission and low ITN use (<25%), have achieved similar efficacies of 69% with two doses of SP 8 weeks apart in Mali , 86% with three monthly doses of artesunate (AS) plus AQ in Senegal , and 69% with six monthly doses of AS plus AQ in Ghana . Taken together, these findings suggest that IPTc would provide a valuable contribution in reducing malaria, by itself or integrated with other intervention strategies, in areas with highly seasonal malaria.
New Evidence on the Delivery of IPT in Children
Few studies have examined the most efficacious and cost-effective means of delivering IPTc. Unlike IPTi and IPTp, which can be deployed as low-cost add-ons to existing frameworks, namely EPI (Expanded Program on Immunization) and antenatal clinics, IPTc does not have a similar existing mechanism. In this issue of PLoS Medicine, Bojang et al. now report important results from a randomised trial of two different modes of delivery . Their findings suggest greater effectiveness in preventing symptomatic malaria when delivered by village health workers (VHWs) compared to reproductive and child health (RCH) trekking clinics. Delivery by VHWs achieved superior coverage, which was better sustained over the study period, and appeared to be more cost effective. The VHW arm had a tendency towards increased ITN usage and greater vaccination coverage. This further supports the important role of VHWs in malaria control in addition to delivering other health services to their communities, and broadly argues in favour of strong primary health care services in communities. While this model is potentially transferrable to other populations, each country considering IPTc implementation will face its own logistic considerations, in identifying, training, resourcing, and rewarding providers of IPTc.
Successful implementation of IPTc in different populations will need tailored drug selection that considers safety, tolerability, drug half-life, and cost, and specific regional circumstances, such as local patterns of drug resistance. Currently, SP/AQ appear to be favoured due to tolerability, efficacy, and affordability, but resistance to these drugs has reached alarming levels in many regions. Indeed, there was some evidence that markers of drug resistance increased in recent trials ,, which probably reflects selection of pre-existing drug resistance; this may compromise the long term efficacy of these drugs. Presently, alternatives to SP and AQ are very limited. Because of the concerns over promoting drug resistance, it is preferable to use drugs in IPTc that are not used as first line for the treatment of malaria cases. The use of SP for treatment of malaria is being phased out in many countries, which may reduce the pressure for drug resistance.
The clinical benefit of IPTc in these recent studies indicates that implementation over a longer period of childhood would be appropriate. Administering IPTc for several years may have a substantial impact on acquired immunity such that a rebound in malaria may be a problem after IPTc ceases. At present, IPTc has been trialled as a short-term intervention (given during one season), and rebound was not observed . The lifetime benefit of IPTc is likely to outweigh problems with rebound, and this potential problem should not be a barrier to implementing IPTc. Nevertheless, it will be important to anticipate and monitor these effects and consider how they might be mitigated.
In What Settings Can IPTc Be Used?
With strong evidence that IPTc is effective in regions experiencing highly seasonal malaria, it remains to be determined at what level of malaria transmission and seasonality IPTc can be justified. It is also unclear how these factors should influence the age at which IPTc should be ceased. Determining the transmission level at which IPTc should be implemented, or continued in settings where malaria is declining, is an important priority. Similarly, the benefit of IPTc and how frequently it should be given in regions with extended malaria seasons or year-round transmission, or in populations outside Africa, is presently not clear. Studies to date have targeted P. falciparum, the major cause of malaria in Africa. However, in many regions Plasmodium vivax is an important cause of malaria, and further studies may be warranted to investigate whether IPTc could be used for this. The added complexity is that P. vivax has a dormant liver stage; clearing blood-stage parasites will not prevent further malaria, even in the absence of re-exposure.
Based on the present evidence, we support the call for the implementation of IPTc as a population-level intervention in specific settings to reduce the burden of malaria in children. However, there is still much we need to know about when, how, and under what circumstances to implement IPTc and how to mitigate the potential impact of increasing drug resistance and impairing immune acquisition. These questions need to be a high priority for ongoing research, not only for IPTc, but alongside other interventions in a multi-faceted approach to malaria control.
ICMJE criteria for authorship read and met: JGB SJR IM JSR FJF. Agree with the manuscript's results and conclusions: JGB SJR IM JSR FJF. Wrote the first draft of the paper: JGB. Contributed to the writing of the paper: JGB SJR IM JSR FJF.
- 1. Schellenberg D, Menendez C, Kahigwa E, Aponte JJ, Vidal J, et al. (2001) Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357: 1471–1477.
- 2. Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, et al. (1999) Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 353: 632–636.
- 3. Greenwood B (2004) The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg 70: 1–7.
- 4. Cairns M, Gosling R, Carneiro I, Gesase S, Mosha JF, et al. (2010) Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants. PLoS ONE 5: e9467. doi:10.1371/journal.pone.0009467.
- 5. Garner P, Gulmezoglu AM (2006) Drugs for preventing malaria in pregnant women. Cochrane Database Syst Rev. CD000169 p.
- 6. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. (2009) Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374: 1533–1542.
- 7. Elliott SR, Beeson JG (2008) Estimating the burden of global mortality in children aged <5 years by pathogen-specific causes. Clin Infect Dis 46: 1794–1795.
- 8. Cisse B, Cairns M, Faye E, O ND, Faye B, et al. (2009) Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS ONE 4: e7164. doi:10.1371/journal.pone.0007164.
- 9. Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, et al. (2008) Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 7: 123.
- 10. Kweku M, Liu D, Adjuik M, Binka F, Seidu M, et al. (2008) Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS ONE 3: e4000. doi:10.1371/journal.pone.0004000.
- 11. Dicko A, et al. (2011) Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide treated bednet in Mali: a randomized, double blind, placebo-controlled trial. PLoS Med 8: e1000407. doi:10.1371/journal.pmed.1000407.
- 12. Konaté AT, et al. (2011) Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide treated bednet in Burkina Faso: a randomized, double blind, placebo-controlled trial. PLoS Med 8: e1000408. doi:10.1371/journal.pmed.1000408.
- 13. Bojang KA, et al. (2011) Comparison of two strategies for the delivery of IPTc in an area of seasonal malaria transmission. PLoS Med 8: e1000409. doi:10.1371/journal.pmed.1000409.